News
Dr Burtness on Subgroup Outcomes for Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer
Barbara Burtness, MD, professor of medicine, Medical Oncology, chief translational research officer, chief, Head and Neck Cancers/Sarcoma, co-leader, Developmental Therapeutics, associate cancer center director for translational research, Yale Cancer Center, discusses subgroup outcomes from the phase 2 E3311 trial (NCT01898494) evaluating primary transoral surgery and postoperative radiation deintensification strategies for patients with human papillomavirus (HPV)–associated oropharynx cancer.
Source: OncLive